Heska (HSKA) Raised to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Heska (NASDAQ:HSKA) from a hold rating to a buy rating in a report issued on Thursday morning. Zacks Investment Research currently has $101.00 target price on the medical research company’s stock.

According to Zacks, “Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska’s state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company’s core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. “

Separately, BidaskClub raised Heska from a hold rating to a buy rating in a research report on Wednesday, October 24th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $106.20.



Shares of HSKA traded down $0.64 during midday trading on Thursday, hitting $91.90. The stock had a trading volume of 29,400 shares, compared to its average volume of 44,750. Heska has a twelve month low of $56.59 and a twelve month high of $114.50. The company has a market capitalization of $713.24 million, a price-to-earnings ratio of 44.40 and a beta of 0.88.

Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, November 6th. The medical research company reported $0.46 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.11. Heska had a return on equity of 11.48% and a net margin of 1.01%. The business had revenue of $30.96 million for the quarter, compared to analyst estimates of $31.14 million. Research analysts expect that Heska will post 1.74 EPS for the current year.

In other Heska news, CEO Kevin S. Wilson sold 3,190 shares of the business’s stock in a transaction that occurred on Friday, November 9th. The stock was sold at an average price of $104.07, for a total transaction of $331,983.30. Following the transaction, the chief executive officer now owns 106,810 shares of the company’s stock, valued at approximately $11,115,716.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director G Irwin Gordon sold 6,700 shares of the business’s stock in a transaction that occurred on Wednesday, November 21st. The stock was sold at an average price of $98.04, for a total value of $656,868.00. Following the transaction, the director now directly owns 34,268 shares in the company, valued at approximately $3,359,634.72. The disclosure for this sale can be found here. Insiders sold a total of 18,702 shares of company stock worth $1,897,809 over the last quarter. Company insiders own 15.90% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. FMR LLC increased its position in Heska by 81.9% during the second quarter. FMR LLC now owns 459,211 shares of the medical research company’s stock worth $47,662,000 after buying an additional 206,814 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Heska by 10.6% during the 2nd quarter. BlackRock Inc. now owns 1,027,636 shares of the medical research company’s stock worth $106,657,000 after acquiring an additional 98,875 shares during the last quarter. Raymond James & Associates increased its holdings in shares of Heska by 53.7% during the 2nd quarter. Raymond James & Associates now owns 106,237 shares of the medical research company’s stock worth $11,026,000 after acquiring an additional 37,139 shares during the last quarter. Grandeur Peak Global Advisors LLC increased its holdings in shares of Heska by 29.9% during the 3rd quarter. Grandeur Peak Global Advisors LLC now owns 99,300 shares of the medical research company’s stock worth $11,252,000 after acquiring an additional 22,850 shares during the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of Heska by 8.5% in the second quarter. Janus Henderson Group PLC now owns 241,885 shares of the medical research company’s stock valued at $25,105,000 after purchasing an additional 18,983 shares during the last quarter. Institutional investors and hedge funds own 89.82% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Featured Article: What does cost of debt say about a company’s financial health?

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply